314 related articles for article (PubMed ID: 33020270)
1. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
Wang C; Tang H; Geng A; Dai B; Zhang H; Sun X; Chen Y; Qiao Z; Zhu H; Yang J; Chen J; He Q; Qin N; Xie J; Tan R; Wan X; Gao S; Jiang Y; Sun FL; Mao Z
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26356-26365. PubMed ID: 33020270
[TBL] [Abstract][Full Text] [Related]
2. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair.
Dong J; Ren Y; Zhang T; Wang Z; Ling CC; Li GC; He F; Wang C; Wen B
Oncol Rep; 2018 Mar; 39(3):912-920. PubMed ID: 29344644
[TBL] [Abstract][Full Text] [Related]
4. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
[TBL] [Abstract][Full Text] [Related]
5. A PARP1-BRG1-SIRT1 axis promotes HR repair by reducing nucleosome density at DNA damage sites.
Chen Y; Zhang H; Xu Z; Tang H; Geng A; Cai B; Su T; Shi J; Jiang C; Tian X; Seluanov A; Huang J; Wan X; Jiang Y; Gorbunova V; Mao Z
Nucleic Acids Res; 2019 Sep; 47(16):8563-8580. PubMed ID: 31291457
[TBL] [Abstract][Full Text] [Related]
6. TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.
Geng L; Zhu M; Luo D; Chen H; Li B; Lao Y; An H; Wu Y; Li Y; Xia A; Shi Y; Tong Z; Lu S; Xu D; Wang X; Zhang W; Sun B; Xu Z
Oncogene; 2024 Feb; 43(9):682-692. PubMed ID: 38216672
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
10. Nuclear PTEN interferes with binding of Ku70 at double-strand breaks through post-translational poly(ADP-ribosyl)ation.
Guan J; Zhao Q; Mao W
Biochim Biophys Acta; 2016 Dec; 1863(12):3106-3115. PubMed ID: 27741411
[TBL] [Abstract][Full Text] [Related]
11. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
Jiang Y; Yam JC; Chu WK
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
[TBL] [Abstract][Full Text] [Related]
12. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
13. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Yang S; Wang XQ
BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
[TBL] [Abstract][Full Text] [Related]
14. Tanshinone I suppresses hepatocellular carcinoma cells growth through targeting DNA double-strand break repair.
Qian Z; Feng N; Geng A
Cancer Biol Ther; 2023 Dec; 24(1):2229958. PubMed ID: 37408176
[TBL] [Abstract][Full Text] [Related]
15. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
[TBL] [Abstract][Full Text] [Related]
16. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
17. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
Bhattacharjee S; Nandi S
IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC.
Sun C; Jing W; Xiong G; Ma D; Lin Y; Lv X; Zhao Y; Ma X; Zhu L; Shen X; Yang M; Qin Z; Cheng Y; Xuan H; Li T; Han L
Cancer Lett; 2022 Feb; 526():180-192. PubMed ID: 34762994
[TBL] [Abstract][Full Text] [Related]
19. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
Reilly NM; Yard BD; Pittman DL
Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
[TBL] [Abstract][Full Text] [Related]
20. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
